Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
$7.49+0.06%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+117.7%
The outlook
Kyverna Therapeutics, Inc. currently reads as neutral based on strong buy — 1.3 avg of 5 analysts, below its 50- & 200-day averages, 43% of the way from its 52-week low to high, avg target +306% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range43% of the way from its 52-week low to high
Price targetAvg target +306% vs current price
Analyst price target
~12-month · 5 analysts$30.40average target+305.9% vs now
Now $7.49
Low $25.00High $33.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$455.4M
52-wk high
$13.67
52-wk low
$2.80
50-day avg
$8.18
200-day avg
$8.27
Trailing P/E
—